Bios Partners β Full Portfolio
9 tracked investments Β· listed companies and verified rows first
Clinical-stage therapeutics company focusing on high-impact cancers and inflammatory diseases.
BiotechFort Worth, US
Daniel Schmitt(Executive Officer, Director)Andrew Mazar(Executive Officer)Paul Lytle(Executive Officer)Leslie Wayne Kreis, Jr.(Director, Promoter)
BoardTodd Thomson(Director)Roger Sawhney(Director)
Board seatAaron G.L. FletcherLeslie W. Kreis, Jr.Β· per SEC Form D Β· $5M raise Β· filed Mar 2024
BiotechFarmington, US
Azim Munivar(Executive Officer, Director, Promoter)
Board seatStella RobertsonTravis WhitfillΒ· per SEC Form D Β· $4.5M raise Β· filed Oct 2022
Cue Biopharma is a clinical-stage biopharmaceutical company developing precision immuno-engineered therapies aimed at functional cures for allergic and autoimmune diseases.
BiotechHealthtechBoston, US
Daniel Baker(Executive Officer)Colin Sandercock(Executive Officer)Dominic Borie(Chief Medical Officer and Head of Research and Development)Sumita Ray(Executive Officer)Daniel Camardo(Director)Viola Meehan(Director)
Board seatAaron G.L. FletcherΒ· per SEC Form D Β· $30M raise Β· filed Nov 2022
Trefoil Therapeutics develops ophthalmologic drugs, with a team focused on drug development and commercialization in the eye-care field.
BiotechHealthtechSan Diego, US
Ralph Bradshaw(Director)Schalon Newton(Executive Officer)David Eveleth(Executive Officer, Director)
BoardChristy Shaffer(Director)
Board seatStella RobertsonΒ· per SEC Form D
ONL Therapeutics is a clinical-stage biopharmaceutical company developing neuroprotective treatments for retinal diseases including retinal detachment, geographic atrophy, and glaucoma.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Executive Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)Loic Couraud(Director)William Brinkerhoff(Director)Mark Hooper(Director)
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.
HardwareHealthtechMedical DevicesDurham, US
Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)Mike Liddell(Manager)Lukas Miller Roush(Manager)
BoardJEFF TERRELL(Director)STANLEY D. LYNALL(Director)
Board seatTravis WhitfillΒ· per SEC Form D Β· $4M raise Β· filed Aug 2018
BiotechHummelstown, US
Stephen C. Rocamboli(Executive Officer, Director)Rifat Pamukcu(Director)Robert Towarnicki(Executive Officer, Director)Roger Sawhney(Director)
BoardJohn Fucci(Director)
Board seatTim Van TreurenΒ· per SEC Form D Β· $42.1M raise Β· filed Jan 2024
BiotechAustin, US
Aaron Fletcher(Director)Joseph Woelkers(Director)Steven Idell(Director)Robert Mills(Director)James Brian Windsor(President and CEO)
Board seatAaron G.L. FletcherΒ· per SEC Form D Β· $15M raise Β· filed Apr 2022
Preclinical biotech developing first-in-class treatments for serious neurodegenerative disorders such as stroke, using its engineered perlecan domain V.
BiotechHouston, US
Chris Garabedian(Director)William Schwieterman(Executive Officer, Director)Fred Callori(Director)
BoardAmanda De La Garza(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.